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Abstract
Background & Aims—Recommendations for patients with Barrett’s esophagus (BE) include
endoscopic surveillance with esophagectomy for early-stage cancer, although new technologies to
ablate dysplasia and metaplasia are available. This study compares the cost-utility of ablation with
that of endoscopic surveillance strategies.
Methods—A decision analysis model was created to examine a population of patients with BE
(mean age 50), with separate analyses for patients with no dysplasia, low-grade dysplasia (LGD), or
high-grade dysplasia (HGD). Strategies compared were: no endoscopic surveillance; endoscopic
surveillance with ablation for incident dysplasia; immediate ablation followed by endoscopic
surveillance in all patients or limited to patients in whom metaplasia persisted, and esophagectomy.
Ablation modalities modeled included radiofrequency, argon plasma coagulation, multipolar
electrocoagulation and photodynamic therapy.
Results—Endoscopic ablation for patients with HGD could increase life expectancy by 3 quality-
adjusted years at an incremental cost of < $6,000, compared with no intervention. Patients with LGD
or no dysplasia can also be optimally managed with ablation, but continued surveillance after
eradication of metaplasia is expensive. If ablation permanently eradicates at least 28% of LGD or
40% of non-dysplastic metaplasias, ablation would be preferred to surveillance.
Conclusions—Endoscopic ablation could be the preferred strategy for managing patients with BE
with HGD. Ablation might also be preferred in subjects with LGD or no dysplasia, but the cost-
effectiveness depends on the long-term effectiveness of ablation and whether surveillance endoscopy
can be discontinued following successful ablation. As further post-ablation data become available,
the optimal management strategy will be clarified.
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Barrett’s esophagus (BE), the premalignant condition associated with esophageal
adenocarcinoma, is a highly prevalent condition, affecting up to 10% of those with chronic
reflux symptoms.1 While the standard management approach to decrease cancer mortality
involves endoscopic surveillance with random biopsy of metaplastic tissue to detect cancer at
a curable stage,2–4 endoscopic mucosal resection, photodynamic therapy (PDT),
radiofrequency ablation (RFA), multipolar electrocoagulation (MPEC) and argon plasma
coagulation (APC) are emerging endoscopic interventions that are efficacious in eliminating
dysplasia and metaplasia.5–14
Under conditions of uncertainty, decision analysis may be helpful to compare competing
strategies of management.15 We conducted a study to determine whether endoscopic ablation
of BE is a cost-effective option to reduce mortality from esophageal adenocarcinoma. In
particular we were interested in identifying the minimal efficacy required for endoscopic
ablation to surpass endoscopic surveillance as the preferred method of management. We chose
to examine ablation in different populations of patients with BE, including patients with high-
grade dysplasia (HGD), low-grade dysplasia (LGD), and no dysplasia in order that our findings
could be applied to these specific patient groups.
Methods
Patients
The hypothetical cohort consisted of 50 year old patients with a diagnosis of BE, defined as
endoscopically identifiable abnormal mucosa with histologically confirmed intestinal
metaplasia. In separate analyses, the cohort was modeled to consist of patients with BE with
HGD, LGD or no dysplasia. It was assumed that all patients would be candidates for diagnostic
and therapeutic procedures, including endoscopy, PDT, RFA, MPEC, APC and
esophagectomy, and would consent to the assigned interventions. The analysis followed the
cohort until age 80 years or death.
Model
A decision analytic model was constructed in TreeAge Pro (TreeAge, Williamstown,
Massachusetts) in the form of a hybrid decision tree (Figure 1A) and Markov process (Figure
1B).15,16 The natural history of the cohort was modeled to examine the costs and outcomes
related to the management of esophageal adenocarcinoma in the absence of surveillance or
other interventions, and compared to various strategies of management proposed for patients
with BE with HGD, LGD or no dysplasia in separate analyses.17–20
Natural History
Costs and discounted quality-adjusted life-years (dQALYs) without surveillance or other
interventions for BE were determined. Cancer would be diagnosed if symptoms prompted
endoscopic evaluation. Depending on the stage of cancer at the time of diagnosis,
esophagectomy or palliation would be performed. Patients with unresectable cancer would be
treated through hospice or palliative care. The outcome of surgery included peri-operative
mortality or morbidity, and survivors of surgery could be cured of cancer or experience
persistent or recurrent disease, rates of which depended upon the stage of cancer at the time of
diagnosis. Death from causes other than esophageal adenocarcinoma was incorporated in an
age-dependent fashion, based on life-tables of U.S. residents for the year 2007.
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Transitions for the model were derived from published literature. To assess key variables a
systematic review of the literature was conducted in the MEDLINE and EMBASE databases
from 1970 to 2008 and abstracts from major gastroenterology scientific meetings from 1999
to 2008 were searched using the terms Barrett’s esophagus, esophageal neoplasm, esophageal
adenocarcinoma, precancerous conditions, and gastroesophageal reflux disease. If no data
existed for a specified transition the authors reached consensus for the best estimate of the
parameter. The details regarding the references from which data were abstracted can be found
in the supplemental information for this article on the journal website.
Ablation Efficacy and Complications
The efficacy and complications associated with ablative therapy for BE were based on
published data of PDT, RFA, MPEC and APC. Details of the systematic reviews of the
literature performed to obtain these data are available in the supplemental information.
Complete remission (CR) was defined as the absence of dysplasia (CR-D) or intestinal
metaplasia (CR-IM) at the specified follow-up point based on histopathological interpretation
of biopsy specimens obtained during specialized surveillance endoscopies. The definition of
CR-IM excluded primary failure of ablation to eliminate all metaplasia as well as recurrence
of metaplasia after ablation, either superficial or subsquamous to account for “buried glands.”
All results were reported on an intention to treat analysis.
Natural History of Barrett’s Esophagus
The NIH sponsored health outcomes research workshop “Advancing an Evidence-Based
Approach to Barrett’s Esophagus” conducted April 9–10, 2007 in Boston, MA, identified
discrepancies between published decision models of BE management. A major cause for these
differences was that published rates of progression and regression between various states of
dysplasia do not produce the cancer incidence reported in national health statistics when used
as inputs in mathematical models. This is likely due to multiple factors including referral bias,
publication bias, stochastic variation in small populations, confounding by indication and the
poor discriminatory value of dysplasia. The current study utilizes methods to ensure that the
model accurately reflects current knowledge of the natural history of BE with respect to
development of esophageal adenocarcinoma. We chose to accomplish this by retaining the
proportional relationship between transitions while altering the absolute values to fit the overall
cancer incidence to the national health statistics. Thus, individual transition rates between
health states were abstracted from published literature and subjected to a conversion factor that
enabled the overall cancer incidence to reflect best estimates derived from published meta-
analyses and the United States National Health Statistics.
In addition to the base-case scenario, extensive sensitivity analyses were conducted using
variations around each of the model transitions supported by published literature (Table 1).
The simulation was carried out until age 80 years or death, and transitions between various
states of metaplasia, dysplasia and cancer were assumed to require at least one year.
Costs and Utilities
The perspective of the analysis was that of a third-party payer, namely the Center for Medicare
and Medicaid Services (CMS). Although CMS generally administers healthcare
reimbursement for enrollees 65 years of age and older, the costs incurred by CMS can also be
used to benchmark reimbursements for other populations since they represent a national
standard that other healthcare insurers follow. Costs, not charges, were the basis for resource
inputs in the analysis.15 Costs were limited to the direct health care costs for delivery of services
related to BE and esophageal adenocarcinoma and excluded direct non-health care costs (borne
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by the patient) and productivity or indirect costs (borne by society). Costs were derived from
2007 CMS data using diagnosis-related groups and Current Procedural Terminology codes for
inpatient resource expenditures and ambulatory payment classification and Current Procedural
Terminology codes for outpatient services rendered. The source for these cost estimates can
be found on the CMS website: http://www.cms.hhs.gov. Medication costs were derived from
Pharmacy Redbook (base case) and varied in the sensitivity analysis by Internet retail sources.
All costs were updated to 2008 estimates using the consumer price index for medical care.
Table 1 presents the cost estimates used in the model.
Utilities, or patient preferences for different health states, were derived from published
literature and used to convert absolute life-years experienced by cohort members to quality-
adjusted life-years (QALYs).21–24 Costs and utilities were discounted at the standard annual
rate of 3% (0–5% in sensitivity analysis).
Outcomes
The primary outcome of the study was the incremental cost per discounted and quality-adjusted
life year (dQALY) between competing strategies of management, also known as the
incremental cost-effectiveness ratio (ICER). The ICER is defined as the difference in cost when
moving from one less expensive but less effective strategy to a more expensive but more
effective strategy, divided by the change in dQALYs between the same two strategies.
Additional outcomes included the mean cost per patient, mean dQALYs per patient and number
of cases of esophageal adenocarcinoma estimated to occur with each modeled strategy.
Sensitivity analyses
All assumptions for the model were varied over a wide range of values in a series of one-way
sensitivity analyses. Ranges were based on published data: in the absence of published data
baseline rates were halved and doubled with adjustment by consensus from the authors.
Parameters associated with greater than 25% variation in outcome and clinically important
parameters were presented in tornado diagrams. Multivariable sensitivity analysis was
performed through Monte-Carlo simulation in which all variables were simultaneously varied
over 1,000 trials (second-order simulations). Results of sensitivity analyses were stratified by
thresholds for dominance (more effective yet less expensive than comparator strategies) and
cost-effectiveness at two levels of willingness to pay (WTP): $50,000 per dQALY gained or
$100,000 per dQALY gained, which allowed identification of strategies yielding the greatest
benefit without exceeding these cost thresholds. WTP indicates the amount that society is
willing to pay in order to achieve a desired health outcome, in this case quality adjusted life-
years.
Patient populations
Current management of patients with BE is stratified by the presence and severity of dysplasia
diagnosed through histopathological examination of esophageal tissue.2–4 All subjects were
assumed to have a correct diagnosis of BE (a change in the esophageal epithelium of any length
that can be recognized at endoscopy and is confirmed to have intestinal metaplasia by biopsy
of the tubular esophagus and excludes intestinal metaplasia of the cardia) on entry to the study.
2 Dysplasia was assumed to consist of cytological and architectural changes in the epithelium
of the esophagus, and was divided into low-grade and high-grade dysplasia based on guideline
recommendations that stratify clinical management based on these features.2–4 Diagnostic
error is problematic in the classification of dysplasia associated with BE and was extensively
modeled to reflect the inter- and intra-observer variation in diagnosis.25–30
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The management options for patients with BE and HGD were modeled to consist of no
intervention, endoscopic surveillance, PDT, RFA, APC or immediate esophagectomy. No
reliable estimates were identified in the literature in which MPEC was used to treat HGD;
therefore this modality was not modeled for this patient group. In the absence of endoscopic
surveillance, cancer would be detected only through development of symptoms at which time
the management of cancer (esophagectomy or palliation) depended on the stage of cancer at
the time of diagnosis. Surveillance utilized endoscopy with 4-quadrant biopsies every 1–2 cm
along the Barrett’s segment every 3 months. After 12 months surveillance intervals were
reassessed based on the highest grade of dysplasia diagnosed during that time period. If HGD
was diagnosed at any time surveillance continued at 3 month intervals, whereas LGD or no
dysplasia extended surveillance to a 12 month interval. Esophagectomy or endoscopic
palliation (stent placement) was utilized for a diagnosis of cancer, depending on the stage of
disease at the time of diagnosis. In the base-case scenario, ablative techniques could be either
ineffective, ablate dysplasia but have persistent intestinal metaplasia (including subsquamous
metaplasia or “buried glands”), or ablate dysplasia and metaplasia. In order to bias the model
against interventions, in sensitivity analyses (including Monte Carlo simulations) we assumed
complete ablation of metaplasia was never achieved and therefore patients were at continued
risk of progression to cancer. Complications of ablation were modeled and included perforation
and stricture formation, in addition to mortality. Endoscopic surveillance was assumed to be
necessary after ablation for HGD and was conducted based on the diagnosed grade of dysplasia.
Esophagectomy was modeled to completely or incompletely remove the Barrett’s segment,
and carried risks of mortality or morbidity at published rates.
Low-grade dysplasia
LGD could be managed by no intervention, endoscopic surveillance, PDT, RFA or APC
ablation with continued surveillance after complete ablation of intestinal metaplasia, or
ablation with surveillance reserved for patients with residual intestinal metaplasia. The base-
case transition inputs for the latter strategy were based on RFA data. No reliable estimates were
identified in which MPEC was used to treat LGD; therefore this modality was not modeled for
this patient group. In the absence of endoscopic surveillance, cancer would be detected only
through development of symptoms at which time the management of cancer (esophagectomy
or palliation) depended on the stage of cancer at the time of diagnosis. Surveillance utilized
endoscopy with 4-quadrant biopsies every 1–2 cm along the Barrett’s segment every 12
months, with esophagectomy reserved for diagnosis of cancer. In the base-case scenario,
ablation could be either ineffective, ablate dysplasia but have persistent intestinal metaplasia
(including subsquamous metaplasia or “buried glands”), or ablate dysplasia and metaplasia.
Again, in order to bias the model against ablation the sensitivity analyses, including Monte
Carlo simulations, assumed complete ablation of metaplasia was never achieved.
No dysplasia
Patients with BE without dysplasia could be managed by no intervention, endoscopic
surveillance using ablation to treat incident dysplasia, immediate endoscopic ablation with
RFA, APC or MPEC with continued endoscopic surveillance after complete ablation of
intestinal metaplasia, or immediate ablation with surveillance reserved for patients with
residual intestinal metaplasia. The base-case transition inputs for the strategy of surveillance
with ablation for incident dysplasia, in addition to the strategy in which ablation was followed
by surveillance limited to those with residual metaplasia were based on RFA data. PDT was
not modeled due to the lack of suitable published data. The modeling of cancer detection,
ablation complications and endoscopic surveillance was identical to the LGD scenario, except
that endoscopic surveillance was modeled on current recommendations published by the
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American Gastroenterological Association that propose a 5-year interval after two endoscopies
confirmed the absence of dysplasia.3,4 Ablation could either be ineffective or ablate intestinal
metaplasia. The presence of subsquamous metaplasia or “buried glands” was incorporated as
a subset of ineffective ablation, which included persistent or recurrent metaplasia after ablation.
Role of the funding source
Support for this study was provided by the National Cancer Institute (R01 CA106773) and
National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK080941), National
Institutes of Health and an unrestricted research grant from BARRX, the company that
developed, manufactures and distributes the radiofrequency ablation device modeled in one
arm of this study. The study was designed, conducted, analyzed and reported without influence
from BARRX. All sensitivity analyses were performed using a deliberately biased model, in
which the least favorable conditions for ablation were used as inputs for the model. Articles
in press were provided by the authors or the company.
Results
Natural History
To calibrate the model and compare it with cohorts reporting natural history data in BE, separate
runs were conducted simulating populations of patients with BE with HGD, with LGD, and
without dysplasia in the absence of interventions to decrease cancer incidence. The model
calculated an annual incidence of esophageal adenocarcinoma among patients with BE and
HGD equal to 2%, among BE and LGD equal to 0.7% and among BE without dysplasia equal
to 0.5%. These results correlated well with recent published estimates of cancer incidence in
these cohorts.17,19,29,31–33
Base-Case Results
High-grade dysplasia: In the absence of interventions to prevent or detect cancer, 50 year old
patients with BE and HGD are predicted to live an additional 12.4 dQALYs and consume on
average $1,859 in discounted health care resources (Table 2). Compared to no surveillance,
strategies employing ablation with PDT, RFA or APC with post-ablation endoscopic
surveillance are calculated to extend life by 3.2 dQALYs. APC and RFA are associated with
cost increases of $19,000–$20,000 per person, while PDT costs are more than $30,000 greater
than no surveillance. Comparison of RFA to no surveillance yields an acceptable ICER of
$5,839 per dQALY gained, while the increase in benefit calculated with PDT requires more
than $32 million per dQALY gained. The strategy of APC is numerically dominated by RFA;
however, the costs and benefits between these ablation techniques are comparable (Figure 2A).
Per 100 patients, 33 fewer cancers are predicted to develop with any of the ablation strategies
compared to no surveillance. While surveillance or immediate esophagectomy increases life
over a strategy of no surveillance, they are dominated by the ablative techniques, since they
yield fewer dQALYs at higher cost.
Low-grade dysplasia: Without intervention, a cohort of patients with BE and LGD is
calculated to accrue 14.7 dQALYs and cost $687 per person in healthcare resources (Table 2).
Ablation with PDT, RFA or APC followed by surveillance in all patients is predicted to increase
life by 1 dQALY compared to no surveillance, with concomitant increases in resource
utilization of approximately $13,000 using APC or RFA, or $27,000 with PDT. Numerically,
RFA followed by surveillance limited to patients in whom metaplasia persists after ablation
dominates all other interventions. However, similar costs and benefits are achieved with this
strategy and APC ablation or RFA with surveillance in all patients (Figure 2B). Per 100 patients,
10 fewer cancers are predicted to develop after ablation of any type compared to no
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surveillance. Compared to ablation, a strategy of surveillance alone is dominated, being both
more expensive and less effective than RFA or APC ablation.
No dysplasia: Following the natural history of patients with BE without dysplasia, 15.2
dQALYs are expected with costs of managing incident cancers averaging $471 per person
(Table 2). The most cost-effective strategy consists of endoscopic ablation (using RFA
parameters) with surveillance limited to patients for whom ablation fails to eradicate
metaplasia, yielding an ICER of $16,286 per dQALY gained over no surveillance. Endoscopic
surveillance using RFA to treat incident dysplasia is dominated by this strategy, as are strategies
employing APC, MPEC or RFA that continue surveillance in patients for whom ablation
successfully eradicates metaplasia. However, if discontinuation of surveillance after successful
ablation is not a clinically viable option, a strategy of surveillance using ablation for incident
dysplasia is equally cost-effective compared to strategies of ablation with APC, MPEC or RFA
with surveillance continued in all patients (Figure 2C).
Sensitivity analysis
High grade dysplasia: All sensitivity analyses conducted in the population of patients with
BE and HGD were biased against ablation by assuming that complete elimination of metaplasia
was never achieved. The remaining variables in the model were subject to one-way sensitivity
analysis using the range of values indicated in Table 1. The results of these analyses (Table 3)
illustrate that ablation is cost-effective as long as at least 25% of patients achieve complete
remission from dysplasia. RFA is the preferred ablation strategy as long as the proportion of
patients with residual HGD after RFA is less than 17%–18%, otherwise APC is preferred. If
the residual HGD after RFA or APC is greater than 23% (WTP $100,000) or 30% (WTP
$50,000), PDT is a cost-effective alternative. The costs of competing ablation strategies impact
the preferred technique, and the range of variation is well within the plausible boundaries of
clinical practice. Figure 3A illustrates the change in the ICER comparing strategies of RFA
versus APC among patients with BE and HGD. The greatest variation in ICER results from
changes in the cost of ablation therapy and the proportion of patients in whom HGD persists
after ablation therapy. Minor changes occur with variation in the complications of ablation
therapy.
Figure 4A presents the results of the Monte Carlo simulation illustrating the proportion of trials
in which each strategy is preferred for management of patients with BE and HGD. Using a
threshold WTP between $0 and $100,000 per dQALY gained, ablation is the preferred strategy
for the majority of trials. RFA, APC and PDT are preferred to surveillance or esophagectomy
in the majority of simulations at even low thresholds, and are preferred in all trials above a
WTP threshold of $50,000 per QALY. No surveillance is viable when the WTP less than
$30,000, while surveillance alone or esophagectomy are preferred in less than 1% of trials
overall.
Low grade dysplasia: As with HGD, all sensitivity analyses conducted in the population of
patients with BE and LGD were biased against ablation by assuming complete elimination of
metaplasia is never achieved. Note that with this assumption, the strategy in which surveillance
is halted after complete ablation of metaplasia becomes identical to the strategy in which
surveillance continues despite absence of metaplasia. Since little difference in outcomes exists
between different ablation techniques these are collectively modeled and compared to
surveillance or no surveillance strategies. The model is sensitive to the proportion of patients
in whom residual LGD persists after ablation. The preferred strategy changes from ablation to
surveillance if the proportion is greater than 54% (WTP $50,000) or greater than 72% (WTP
$100,000) (Table 3). When the cost of ablation exceeds $15,000 (WTP $50,000) or $26,000
(WTP $100,000), surveillance also becomes cost-effective. No variation in the cost of
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surveillance endoscopy or the rate of complications associated with ablation within the ranges
identified in Table 1 change the preferred strategy (Figure 3B).
Figure 4B presents the results of the Monte Carlo simulation illustrating the proportion of trials
in which each strategy was preferred for management of patients with BE and LGD. Using a
threshold WTP between $0 and $100,000 per dQALY gained, ablation is the preferred strategy
in the majority of trials. No surveillance is preferred in the majority of trials when the WTP
drops below $30,000 per QALY. Surveillance is preferred in less than 1% of trials.
No dysplasia: In the base case scenario the optimal strategy requires discontinuation of
surveillance after successful ablation of metaplasia. Sensitivity analysis reveals this to be a
robust finding as long as complete ablation of metaplasia is achieved in at least 40% (WTP
$100,000 per dQALY gained) to 47% (WTP $50,000 per dQALY gained) of cases (Table 3).
If ablation is completely successful in less than 40% of cases then surveillance is optimal.
Comparing endoscopic surveillance to ablation with no surveillance after complete ablation,
the influential variables include the proportion of patients in whom complete ablation of
metaplasia is achieved and the cost of ablation. The cost of surgery or endoscopy influences
the cost-effectiveness to a smaller degree, while patient preference (utility) of the post-
esophagectomy state has little impact on the ICER (Figure 3C). The effectiveness of surgery
or complications of surgery and ablation also do not impact the preferred strategy (data not
shown).
Monte Carlo simulation reveals that ablation followed by surveillance limited to those with
residual metaplasia is optimal in up to 85% of trials, increasing with higher levels of willingness
to pay (Figure 4C). Surveillance using ablation for incident dysplasia is preferred in 20% or
fewer trials, depending on the WTP. More importantly, ablation with continued surveillance
in all patients is optimal in 1% or less of trials. No surveillance is preferred in this population
more often than either of the two latter strategies, and is optimal among all strategies if the
WTP is less than $25,000.
Discussion
Our analysis of the cost-effectiveness of endoscopic ablation of BE demonstrates that ablation
of HGD in subjects with BE is probably cost-effective, capable of providing over three years
of additional quality-adjusted life expectancy at a cost of less than $6,000 per dQALY gained.
Despite biasing the model against ablation, this strategy is estimated to be more effective and
less costly than surveillance or esophagectomy for patients with BE and HGD. The
effectiveness of the different ablation techniques appears similar, with variation only in costs.
In LGD, ablative therapy may be cost-effective compared to surveillance; however, continued
endoscopic surveillance of patients after successful reversion to normal squamous epithelium
yields little benefit. In the setting of non-dysplastic BE, ablation may be the preferred strategy
if the proportion of patients in whom complete and permanent ablation is achieved is greater
than 40% (WTP $100,000 per dQALY gained), and endoscopic surveillance can be
discontinued in patients in whom ablation is successful.
A goal of decision analysis is to illuminate important gaps in our knowledge and to highlight
key questions that must be answered in order to determine whether a proposed intervention
should be implemented. In the present analysis, perhaps the single most important “unknown”
is the prognosis of subjects who have undergone ablation, and are now endoscopically and
histologically normal. Are these patients no longer at risk for developing cancer, and can they
be released from endoscopic surveillance? Currently insufficient data exist to answer this
question and presently, we and others are retaining these subjects in endoscopic surveillance
programs. Because of uncertainty regarding the prognosis of these patients, we modeled both
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the currently practiced strategy of maintaining surveillance in these subjects, as well as the
strategy of releasing successfully ablated patients from surveillance. Recent studies have
questioned the benefit of endoscopic surveillance and our analyses illustrate only a nominal
benefit of endoscopic surveillance.34 In all scenarios continuation of surveillance after
successful ablation is not a preferred strategy. Whether a strategy of selective follow-up of
patients based on ablation results can be justified awaits further outcomes data from cohorts
having undergone ablative therapy.
Ablative strategies may appear cost-effective either by being superior modes of therapy, or
because the comparator strategies are poor interventions. This analysis suggests that
endoscopic surveillance may be an especially inefficient and cost-ineffective strategy. Previous
studies have demonstrated the poor cost-effectiveness of surveillance to decrease mortality
from esophageal adenocarcinoma.35 From a broad perspective, it is more effective (and cost-
effective) to prevent cancer than to treat cancer. It is the intent of this analysis not to promote
one specific preventive or ablative technique, but rather to highlight the fundamental
advantages of interventions that reduce cancer incidence, especially if the complications
associated with the intervention are uncommon. This concept is exemplified in the model of
no dysplasia. Ablation is preferred in this group, but only if we are willing to forego continued
surveillance for patients in whom metaplasia has been eliminated, even if there remains a small
risk of progression to malignancy.
The sensitivity analyses illustrate the key factors influential in the decisions regarding
management of patients with BE. Common to all scenarios is the dependence of the results on
the efficacy of ablation, the durability of these effects and ultimately whether cancer incidence
is reduced after ablation is achieved. Thus, the effectiveness and cost-effectiveness of ablative
methods will not be fully understood until such data can be accumulated from patients enrolled
in research protocols. The costs of various interventions are also influential but rarely change
the order of preferred strategies. Other variables, including the risk or cost of complications,
the effectiveness of surgery and the preference of patients for various health states (utilities)
do not appear to influence the outcomes.
Our analysis has some important limitations. The values used to populate the model were
derived from selected groups of patients in most cases referred to specialized centers and prone
to selection and publication bias. Because we felt it important to have our model conform to
national cancer statistics we calibrated the natural history of the model to the lowest rates of
cancer incidence reported in published literature, thereby biasing our results against the use of
any intervention. Also, we have assumed that subjects in whom ablation was unsuccessful or
in whom metaplasia recurred after ablation retained the cancer risk of their initial level of
dysplasia. Some data suggest that a failed attempt at ablation may actually result in the
expression of precancerous markers that could potentially put these patients at a higher risk
for neoplasia.36
We chose to examine the management of patients with established BE in this study while
excluding the question of whether screening to identify this group is cost-effective. Our earlier
work compared the relative impact of screening vs. surveillance and found that while screening
50-year old white men with heartburn to detect cancer and dysplasia would likely be cost-
effective, continued surveillance of patients without dysplasia was an expensive strategy.35
The current study expands upon this theme in which surveillance is illustrated to be both
ineffective and costly, due to the relatively infrequent development of dysplasia and cancer
among patients not diagnosed with dysplasia during the initial screening and the inaccuracy of
dysplasia as a marker of progression to malignancy. Development and validation of biomarkers
that better predict the development of cancer among people with BE would improve the
effectiveness of surveillance, as well as enhance selection of patients most appropriate for
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ablation.37 A greater question raised through these studies is whether any intervention for
patients diagnosed with BE without dysplasia is warranted. Based on the marginal differences
in cost-effectiveness between ablation and surveillance, perhaps even ablation in non-
dysplastic BE requires resources that are beyond the threshold society is willing to expend;
however, this study focuses on optimizing management of patients with established BE while
our previous work focused comparing the benefit of the initial screen vs. subsequent
surveillance to detect early cancer. More broadly, the results of this study are not limited to
valuation of endoscopic ablation but rather provide a set of general principles upon which
interventions may be compared to current standards of care. The threshold analyses provided
in this paper may be used as a benchmark for any future intervention developed to reduce
mortality from esophageal adenocarcinoma. The main concept we wish to convey is that
strategies that reduce cancer development should be preferred over strategies that rely on early
diagnosis of cancer.
Our data are in line with previous studies of cost-effectiveness of ablation for BE compared to
either surveillance or esophagectomy.38–41 Although absolute results have varied across
studies, these have shown ablation to be superior to comparator arms in the treatment of HGD.
Even when ablation is used to treat incident dysplasia identified through surveillance, the
recurrent costs of endoscopy, poor reproducibility of histological interpretation and low
incidence of cancer in subjects under surveillance combine to make endoscopic surveillance
strategies unfavorable, especially in those with non-dysplastic disease.
In conclusion, our data suggest that endoscopic ablation may be the preferred strategy for the
management of BE with HGD. Ablation may also be preferred in subjects with LGD and non-
dysplastic disease, but the cost-effectiveness of this strategy is highly dependent on the long-
term effectiveness of ablation therapy and whether surveillance endoscopy can be discontinued
following a successful ablative procedure. As further post-ablation data become available, the
optimal strategy to be implemented will be clarified.
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Figure 1A. Decision Tree: Patient options at the decision node (square) include: no
surveillance, surveillance, ablation with surveillance for all patients, or ablation without
surveillance for those in whom complete ablation of metaplasia is achieved. Among patients
treated with ablation, complications leading to either morbidity or mortality may occur, dictated
by the probabilities at the chance nodes (circles). Mortality results in termination of the
simulation. All other patients may have persistent dysplasia, no dysplasia but persistent
metaplasia, or complete ablation of dysplasia and metaplasia, dictated by the probabilities at
the chance nodes, which differ according to patient category (high-grade, low-grade or no
dysplasia) and ablation type. Patients not experiencing mortality from ablation enter the
Markov Model (Figure 1B), as do patients who are managed by the surveillance or no
surveillance strategies.
Figure 1B. Markov Model: Patients can reside in one of seven major states: Patients without
Barrett’s esophagus (BE); patients with BE, without dysplasia or cancer; patients with BE and
low-grade dysplasia (LGD); patients with BE and high-grade dysplasia (HGD); patients with
adenocarcinoma of the esophagus; patients who have had esophagectomy; and death from
adenocarcinoma of the esophagus, complications of surgery, endoscopy, or other causes. The
arrows indicate the possible transitions from one state to another in each cycle. Dashed lines
indicate transition allowed only with ablative therapies.
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Cost-effectiveness analysis: The base-case results are depicted for high-grade dysplasia (HGD
- Panel A), low-grade dysplasia (LGD - Panel B) and no dysplasia (Panel C). The abscissa
depicts discounted quality-adjusted life-years (dQALYs) and the ordinate depicts the costs per
patient. The lines connect the non-dominated strategies, and the slope of each line represents
the incremental cost-effectiveness ratio (ICER) between strategies.
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One-way sensitivity analyses: Tornado diagrams for high-grade dysplasia (HGD - Panel A),
low-grade dysplasia (LGD - Panel B) and no dysplasia (Panel C) depict the range of incremental
cost-effectiveness ratios by varying each of the examined variables. APC: argon plasma
coagulation; PDT: photodynamic therapy; RFA: radiofrequency ablation; MPEC: multipolar
electrocoagulation; EGD: esophagogastroduodenoscopy.
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Monte-Carlo simulation: Optimal strategy stratified by willingness to pay in populations
comprised of high-grade dysplasia (HGD - Panel A), low-grade dysplasia (LGD - Panel B)
and no dysplasia (Panel C). The lines illustrate the proportion of trials in which each strategy
was calculated to comprise the optimal strategy, defined as the strategy associated with the
greatest dQALYs obtainable within a willingness to pay of $0 to $100,000 per discounted
quality-adjusted life-year gained. BE: Barrett’s esophagus; APC: argon plasma coagulation;
PDT: photodynamic therapy; RFA: radiofrequency ablation.
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Table 1
Variables
Description Base Low High
Costs ($U.S. 2008)
cost of cancer (annual) $47,064 $10,000 $50,000
cost of surveillance EGD (with biopsies) $886 $350 $1,000
cost of surgical morbidity $35,398 $17,000 $70,000
cost of cancer palliation $1,652 $1,000 $5,000
cost of perforation during ablation $54,220 $10,000 $100,000
cost of post surgery state (annual) $1,426 $500 $2,000
cost of RFA $7,506 $3,500 $15,000
cost of APC $5,629 $2,500 $12,000
cost of PDT $20,000 $10,000 $40,000
cost of MPEC $6,568 $3,500 $14,000
cost of ablation-related stricture $2,112 $900 $3,000
cost of esophagectomy $24,665 $10,000 $40,000
cost of clinic visit $60 $25 $100
cost of generic proton pump inhibitor
(annual)
$91 $76 $157
cost of high-dose proton pump inhibitor
(annual)
$3,652 $599 $4,529
discount rate 0.03 0.03 0.05
Transition Rates
HGD to cancer 0.0303 0.5 0.9
HGD to LGD 0.0385 0.05 0.1
HGD to ND BE 0.0055 0.01 0.15
LGD to cancer 0.0138 0.005 0.05
LGD to HGD 0.0275 0.01 0.078
LGD to ND BE 0.3465 0.5 0.8
ND BE to cancer 0.0028 0.001 0.1
ND BE to HGD 0.0055 0.0028 0.083
BE to LGD 0.0275 0.01 0.078
mortality in unresectable cancer (annual) 0.9 0.8 1
mortality from non-cancer causes Varies with age
Efficacy of Therapy
% complete ablation of metaplasia with PDT 0.60 0.00 0.80
In dysplasia* 0.58 0.00 0.71
% complete ablation of metaplasia with RFA 0.82 0.10 0.90
In dysplasia* 0.64 0.10 0.90
% complete ablation of metaplasia with APC 0.65 0.32 1.00
In dysplasia* 0.62 0.28 0.97
% complete ablation of metaplasia with
MPEC
0.75 0.62 0.81
% cancer patients who undergo
esophagectomy
0.80 0.50 1.00
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Description Base Low High
% cancer cure with esophagectomy 0.80 0.60 0.90
% residual metaplasia with esophagectomy 0.04 0.03 0.10
% residual HGD with esophagectomy 0.01 0.00 0.03
% residual HGD with PDT 0.12 0.00 0.50
% residual HGD with RFA 0.15 0.00 0.33
% residual HGD with APC 0.19 0.00 0.56
% residual LGD with PDT 0.08 0.00 0.43
% residual LGD with RFA 0.03 0.00 0.05
% residual LGD with APC 0.19 0.00 0.28
Complications of Therapy
mortality with EGD 0.000021 0 0.00005
mortality from esophagectomy 0.05 0.025 0.1
mortality from esophagectomy with
perforation
0.08 0.05 0.15
morbidity from esophagectomy 0.15 0.05 0.4
morbidity from esophagectomy with
perforation
0.2 0.1 0.5
perforation with PDT 0.003 0.001 0.01
perforation with APC 0.0045 0.001 0.01
perforation with RFA 0.0005 0.0001 0.001
perforation with MPEC 0.0005 0.0001 0.001
stricture with PDT 0.185 0.1 0.3
stricture with RFA 0.025 0.01 0.05
stricture with APC 0.026 0.01 0.05
stricture with MPEC 0.025 0.01 0.05
Misdiagnosis
Actual State Diagnosed State
No Dysplasia LGD 0.145 0.01 0.2
No Dysplasia HGD 0.01 0 0.02
No Dysplasia Cancer 0.01 0 0.02
LGD No Dysplasia 0.175 0.01 0.2
LGD HGD 0.083 0.01 0.1
LGD Cancer 0.05 0.01 0.1
HGD No Dysplasia 0 0 0.01
HGD LGD 0.115 0.01 0.2
HGD Cancer 0.11 0.01 0.2
Cancer LGD 0.05 0.01 0.1
Cancer HGD 0.175 0.01 0.2
Utilities
utility of Barrett’s without dysplasia 1 0.79 1
utility of LGD 1 0.8 1
utility of HGD 1 0.8 1
utility of cancer 0.5 0 1
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Description Base Low High
utility of post-esophagectomy state 0.97 0.46 1
*
One-way sensitivity analyses used 0% complete ablation with endoscopic ablation EGD: esophagogastroduodenoscopy; RFA: radiofrequency ablation;
APC: argon plasma coagulation; MPEC: multipolar electrocoagulation; PDT: photodynamic therapy; HGD: high-grade dysplasia; LGD: low-grade
dysplasia; ND: no dysplasia; BE: Barrett’s esophagus



































































































































































































































































































































































































































































































































































































































































































































































































































































Residual HGD after Ablation Assume No Complete Ablation of Metaplasia
RFA: ≤ 0.17 RFA Cost-Effective
RFA: > 0.17 APC Cost-Effective (WTP $100,000)
RFA: > 0.18 APC Cost-Effective (WTP $50,000)
RFA/APC: > 0.23 PDT Cost-Effective (WTP $100,000)
RFA/APC: > 0.30 PDT Cost-Effective (WTP $50,000)
RFA/APC/PDT: > 0.75 Surveillance Cost-effective (WTP $100,000)
Cost of Ablation
RFA: ≤ $8,500 RFA Cost-Effective
RFA: > $9,000 APC Cost-Effective (WTP $100,000)
RFA: > $11,000 APC Cost-Effective (WTP $50,000)
RFA/APC: > $17,500 PDT Cost-Effective (WTP $100,000)
RFA/APC: > $18,500 PDT Cost-Effective (WTP $50,000)
LGD
Residual LGD after Ablation+ Assume No Complete Ablation of Metaplasia
< 54% Ablation Cost-Effective (WTP $50,000)
< 72% Ablation Cost-Effective (WTP $100,000)
≥72% Surveillance Cost-Effective
Cost of Ablation+
≤$15,000 Ablation Cost-Effective (WTP $50,000)
< $26,000 Ablation Cost-Effective (WTP $100,000)
≥$26,000 Surveillance Cost-Effective
Cost of EGD+
No threshold identified Ablation Cost-Effective or Dominant
Perforation or Stricture with Ablation+
No threshold identified Ablation Cost-Effective or Dominant
No Dysplasia
Complete Ablation of Metaplasia+
≤40% Surveillance Cost-Effective
> 40% Ablation Without Surveillance Cost-Effective (WTP $100,000)
> 47% Ablation Without Surveillance Cost-Effective (WTP $50,000)
Ablation without surveillance always preferred over ablation with surveillance
Cost of Ablation+
No threshold identified Ablation without surveillance cost-effective
HGD: high-grade dysplasia; LGD: low-grade dysplasia; RFA: radiofrequency ablation; APC: argon plasma coagulation; PDT: photodynamic therapy;
EGD: esophagogastroduodenoscopy; WTP: willingness to pay
+
Ablation based on RFA parameter estimates
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